


# BCG

: 1 1

BCG  
 Bacillus Calmette-Guérin (BCG) (immunomodulatory effect)가 (1) 가 (granulomatous prostatitis) BCG (intravesical BCG instillation) 가 (BCG induced prostatitis) 가 BCG (2). BCG BCG (3). BCG BCG 가 (attenuation) BCG (carcinoma in situ) . 1970 가 (4). BCG 0-0.9 % (5, 6). LaFontaine (1) BCG (cystoprostatectomy) 75 % 70 % BCG (5). BCG (prostatic duct) (extravasation) BCG가 (resolution stage)

69 가 1 2 가 T1, G BCG 6.0 ng/ml 39 ml (contour bulging) 가 (systemic sextant biopsy) (caseation necrosis) (AFB) (Isoniazid,400mg)



A  
Fig. 1. A. Axial transrectal sonogram demonstrates a well defined hypoechoic lesion in the peripheral gland with contour bulging (arrow).  
B. Color Doppler sonogram demonstrates hypovascular nature of the lesion.




Fig. 2. MRI performed at the time of initial diagnosis of bladder cancer (two months prior to figure 2)  
A. Contrast enhanced T1-weighted image demonstrates a well-enhanced polypoid mass in the bladder.  
B. Contrast enhanced T1-weighted image at the level of prostate demonstrates strong enhancement of the central gland (arrow) and a focal area of left peripheral gland (arrow head), which probably represents the invasion from bladder cancer.

(5),  
Miyashita (7) BCG

가

가

(Fig. 2).

BCG

BCG

BCG

BCG

BCG

1. Meyers FH, Jawetz E, Goldfien A. *Review of medical pharmacology*, 7th ed. Los Altos, CA: Lange 1980:525-614
2. LaFontaine PD, Middleman BR, Graham SD Jr, Sanders WH. Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy. *Urology* 1997;49:363-366
3. Lamm DL, Stogdill VD, Stogdill BJ, Crispin RG. Complications of Bacillus Calmette- Guerin immunotherapy in 1,278 patients with bladder cancer. *J Urol* 1986;135:272-274
4. Catalona WJ, Ratliff TL. Bacillus Calmette-Guerin and superficial bladder cancer. Clinical experience and mechanism of action. *Surg Annu* 1990;22:363-378
5. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of Bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. *J Urol* 1992;147:596-600
6. Steg A, Adjiman S, and Debre B. BCG therapy in superficial bladder tumors-complications and precautions. *Eur Urol* 21(suppl 2) 1992: 35-40
7. Miyashita H, Troncoso P, Babaian RJ. BCG-induced granulomatous prostatitis: a comparative ultrasound and pathologic study. *Urology* 1992;39:364-367

## **BCG Induced Granulomatous Prostatitis: A case report<sup>1</sup>**

Min Hoan Moon, M.D., Chang Kyu Seong, M.D., Kyoung Ho Lee, M.D., Seung-Hyup Kim, M.D.

*<sup>1</sup>Department of Radiology, Seoul National University College of Medicine, and the Institute of Radiation Medicine, SNUMRC*

Granulomatous prostatitis was relatively uncommon until the introduction of intravesical BCG for the treatment of bladder cancer. Since that time, there has been an increase in the number of cases of granulomatous prostatitis, but the domestic literature contains no report. We recently encountered a classic case of BCG induced granulomatous prostatitis and describe this case, including its radiologic findings.

**Index words :** Prostate, diseases  
Prostate, US  
Prostatitis

Address reprint requests to : Seung-Hyup Kim, M.D., Department of Radiology Seoul National University Hospital,  
28, Yongon-dong, Chongno-gu, Seoul, 110-744, Korea.  
Tel. 82-2-760-2584 Fax. 82-2-743-6385 E-mail: kimsh@radcom.snu.ac.kr

